Oral Idarubicin and Low Dose Cytarabine as the Initial Treatment of Acute Myeloid Leukemia in Elderly Patients

References

• Housset M., Daniel M. T., Degos L. Small doses of ara-C in the treatment of myeloid leukemia: Differentiation of myeloid leukemia cells?. Br. J. Haematol 1982; 51: 125–129
   PubMed Web of Science ®Google Scholar
• Sachs L. The differentiation of myeloid leukemia cells: new possibilities for therapy. Br. J. Haematol 1978; 40: 509–517
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Jasperse D. M., Simon R., Friedman M. A. A critical appraisal of low dose cytosine arabinoside in patients with acute non lymphocytic leukaemia and myelodysplastic syndromes. J. Clin. Oncol 1986; 4: 1857–64
   PubMed Web of Science ®Google Scholar
• Bolwell B. J., Cassileth P. A., Gale R. P. Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review. Leukemia 1987; 1: 575–579
   PubMed Web of Science ®Google Scholar
• Ganzina F., Pacciarini M. A., Di Pietro N. Idarubicin (4 demethoxydaunorubicin): a preliminary overview of pre-clinical and clinical studies. Invest. New Drugs 1986; 4: 85–105
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Rigal-Huguet F., Hurteloup P., Guy H., Milpied N., Pris J. Treatment of acute myeloid leukemia in elderly patients with oral idarubicin as a single agent. Eur. J. Haematol 1989; 42: 182–185
   PubMed Web of Science ®Google Scholar
• WHO. Handbook for Reporting Results of Cancer Treatment. WHO Offset publication no. 48. World Health Organization, Geneva 1979
   Google Scholar
• Baker M. A. The management of leukemia in the elderly. Bailliere's Clinical Haematology 1987; 1: 427–449
   PubMedGoogle Scholar
• Champlin R. E., Gajewski J. L., Golde D. W. Treatment of acute myelogenous leukemia in the elderly. Semin. Oncol 1989; 16: 51–56
   PubMed Web of Science ®Google Scholar
• Brincker H. Estimate of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat. Rep 1985; 69: 5–11
   PubMedGoogle Scholar
• Rees J. K. H., Swirsky D., Gray R. G., Hayhoe F. G. J. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; ii: 1236–1241
   Google Scholar
• Peterson B. A., Bloomfield C. D. Treatment of acute non lymphocytic leukaemia in elderly patients. A prospective study of intensive chemotherapy. Cancer 1977; 40: 647–652
   PubMed Web of Science ®Google Scholar
• Keating K. A., McCredie K. B., Benjamin R. S. Treatment of patients over 50 years of age with acute myelogenous leukaemia with a combination of rubidazone and cytosine arabinoside, vincristine and prednisone (ROAP). Blood 1981; 58: 584–590
   PubMed Web of Science ®Google Scholar
• Tucker J., Thomas A. E., Gregory W. M. Acute Myeloid Leukemia in Elderly Adults. Haematol. Oncol 1990; 8: 13–21
   PubMed Web of Science ®Google Scholar
• Yates J., Glidewell O., Wiernik P. Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute leukemia. A CALGB study. Blood 1982; 60: 454–462
   PubMed Web of Science ®Google Scholar
• Kahn B., Begg C. B., Mazza J. J. Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J. Clin. Oncol 1984; 2: 865–870
   PubMed Web of Science ®Google Scholar
• Löwenberg B., Zittoun R. Kerkhofs. On the value of remission induction chemotherapy in Elderly patients of 65+ years with a Acute Myeloid Leukemia: A Randomized Phase III Study of the European Organization for Research and Treatment of Cancer Leukemia Group. J. Clin. Oncol 1989; 7: 1268–1274
   PubMed Web of Science ®Google Scholar
• Herzig R. H., Hines J. D., Herzig G. P. Cerebellar toxicity with high dose cytosine arabinoside. J. Clin. Oncol 1987; 5: 927–932
   PubMed Web of Science ®Google Scholar
• Preisler H. D., Raza A., Barcos M. High Dose Cytosine Arabinoside as the initial treatment of poor risk patients with acute non lymphocytic leukemia: a Leukemia Intergroup Study. J. Clin. Oncol 1987; 5: 75–82
   PubMed Web of Science ®Google Scholar
• Lazarus H. M., Vogler R., Burns P., Winton E. F. High dose Cytosine Arabinoside and Daunorubincin as Primary Therapy in Elderly patients with acute myelogenous leukemia. Cancer 1989; 63: 1055–1059
   PubMed Web of Science ®Google Scholar
• Harousseau J. L., Castaigne S., Milpied N., Marty M., Degos L. Treatment of acute non lymphoblastic leukemia in elderly patients. Lancet 1984; ii: 288
   Google Scholar
• Castaigne S., Daniel M. T., Tilly H. Does treatment with ara-C in low dosage cause differentiation of leukemia cells. Blood 1983; 62: 85–86
   PubMed Web of Science ®Google Scholar
• Ishikura H., Sawada H., Okazaki T. The effect of low dose ARA-C in acute non lymphoblastic leukaemias and atypical leukemia. Br. J. Haematol 1984; 58: 9–18
   PubMed Web of Science ®Google Scholar
• Seban C., Archimbaud E., Coiffier B. Treatment of acute myeloid leukemia in Elderly Patients. A retrospective study. Cancer 1988; 61: 227–231
   PubMed Web of Science ®Google Scholar
• Powell B. L., Capizzi R. L., Muss H. B. Low dose Ara-C therapy for acute myelogenous leukemia in elderly patients. Leukemia 1989; 3: 23–28
   PubMed Web of Science ®Google Scholar
• Tilly H., Castaigne S., Bordessoule D. Low Dose Cytarabine versus Intensive Chemotherapy in the Treatment of Acute Non Lymphocytic Leukemia in the Elderly. J. Clin. Oncol 1990; 8: 272–279
   PubMed Web of Science ®Google Scholar
• Bezwoda W. R., Dansey R. D. Idarubicin plus Cytarabine versus Doxorubicin plus Cytarabine in Induction Therapy for Acute Non Lymphoid Leukemia: A randomized trial. Leukemia and Lymphoma 1990; 1: 221–225
   PubMedGoogle Scholar
• Lowenthal R. M., Chesterman C.N., Griffiths J. D. Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. Cancer Treat., Rep 1987; 71: 1279–1281
   PubMedGoogle Scholar
• Helg C., Chapuis B., Grob J. P., Pugin P. Leucémies myéloïdes aiguës de mauvais pronostic: traitement par la déméthoxydaunorubicine (Idarubicine) per os et cytarabine à doses réduites par voie sous cutanée. Schweiz. Med. Wschr 1990; 120: 548–552
   PubMedGoogle Scholar
• Fenaux P., Lai J. L., Gardin C., Bauters F. Cytogenetics are a predictive factor of response to low Dose ARA-C in Acute Myelogenous Leukemia in the elderly. Leukemia 1990; 4: 312
   PubMed Web of Science ®Google Scholar
• Büchner T., Hiddemann W., Koenigsmann M., Zuehlsdorf M., Woermann B., Boeckmann A., Agrion Freire E., Innig G., Maschmeyer G., Ludwig W. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy for acute leukemias at higher age or after relapse. Hamatol. Bluttransfus 1990; 33: 724–731
   Google Scholar